Randomized phase II study of best-available 5-fluorouracil (5-FU) versus weekly paclitaxel in gastric cancer (GC) with peritoneal metastasis (PM) refractory to 5-FU-containing regimens (JCOG0407).

Hiroya Takiuchi,Haruhiko Fukuda,Narikazu Boku,Yoshihisa Shimada,Junichiro Nasu,Yasuo Hamamoto,Shuichi Hironaka,Kensei Yamaguchi,Atsuo Takashima,Atsushi Ohtsu

Randomized phase II study of best-available 5-fluorouracil (5-FU) versus weekly paclitaxel in gastric cancer (GC) with peritoneal metastasis (PM) refractory to 5-FU-containing regimens (JCOG0407).

2010

Hiroya Takiuchi
Haruhiko Fukuda
Narikazu Boku
Yoshihisa Shimada
Junichiro Nasu
Yasuo Hamamoto
Shuichi Hironaka
Kensei Yamaguchi
Atsuo Takashima
Atsushi Ohtsu

4052 Background: 5-FU containing regimen is the most commonly used first-line treatment for advanced GC. However, there is no standard treatment after failure of first-line 5-FU-based regimen. In p...

Keywords:

Fluorouracil
Physical therapy
Cancer
Paclitaxel
Phases of clinical research
Metastasis
Cancer research
Intensive care medicine
Medicine
Standard treatment
Regimen
Internal medicine
peritoneal metastasis
Refractory
Oncology
weekly paclitaxel

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations